This European Commission Ready to start Legal process Anglo-Swedish company that opposes the production of the vaccine AstraZeneca There are already 27 vaccines in short supply.
As the magazine revealed political, Which references Five diplomats The European Commission, which has not yet been determined by the European Commission, put forward this initiative in a proposal. Ambassador meeting last Wednesday. According to the publication, at that meeting, most EU countries said they would support a lawsuit against this company because the company failed to deliver vaccine doses against 27 companies.
A diplomat has also been clarifying, always based on political, The purpose of legal proceedings is Mandatory AstraZeneca to provide the dose specified in your contract With the European Union.
The two participants in the diplomatic conference also explained that there is a deadline this weekend, within which EU countries must approve the start of legal proceedings.
AstraZeneca Provoked the anger of the European Union last January When he said that he was unable to provide the initial dose to the drug area.
At the end of the first quarter of 2021, the company delivered 30 million Dose to EU countries, Instead of the 100 million promised Remember that Politico was in the contract with the community authorities. This shortage has severely hindered vaccination campaigns in EU countries.
The company expects it will deliver about 70 million Dose at the end Second quarter According to the publication, it should have delivered all 300 million doses stipulated in the EU contract that year.
On the other hand, according to the information consulted by Europa Press of the “Science News and Information Service” of the Ministry of Science and Technology (European), according to the low platelets associated with the Oxford/AstraZeneca vaccine, the connection around the rare thrombus is still “Intensify contact.” Innovative spirit.it’s a Before the new publication -Pending peer review-This Tuesday, Andreas Greinacher, a researcher from Greifswald University in Germany, shared the research, which further clarifies this very rare The mechanism by which the phenomenon occurs is estimated that only 1 out of every 100,000 vaccinators will develop the disease.
Simultaneous research Added the list of possible “culprits” and suspected the existence of other adenovirus-based vaccines Will be affected, how many people will be affected, who are susceptible, and whether it is possible to fundamentally solve the problem to eradicate this rare side effect. Greinacher said at a telematics conference on Tuesday: “You can’t tell the complete story. It will take many years, but the key aspects are now clear.” SINC agent.
Researchers believe that certain substances in the vaccine will interact with a protein on platelets called platelet factor 4 (PF4) to trigger an autoimmune response.In addition, they found One of the vaccine components, EDTA (ethylenediaminetetraacetic acid) is present in a “relatively high” amount, causing capillary leakage in mice.